Novo Nordisk AS (NOVO B)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013597)
◆英語タイトル:Novo Nordisk AS (NOVO B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013597
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:174
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Novo Nordisk A/S (Novo Nordisk), a subsidiary of Novo A/S discovers, develops and manufactures innovative biological medicines. It focuses at developing drugs for treating diabetes and other serious chronic conditions including hemophilia, growth disorders and obesity. The company’s product portfolio includes new-generation insulins, modern insulins, human insulins, oral antidiabetic agents, diabetes devices and others. Novo Nordisk also offers biopharmaceuticals for treating haemostasis, human growth hormone products and hormone replacement therapy. With subsidiaries in Europe, North America, Asia, Latin America and Australia, it markets its products in several countries worldwide. Novo Nordisk is headquartered in Bagsvaerd, Denmark.

Novo Nordisk AS (NOVO B) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 7
List of Figures 8
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Novo Nordisk AS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 12
Novo Nordisk AS, Medical Devices Deals, 2011 to YTD 2017 14
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deal Details 22
Venture Financing 22
Inozyme Pharma Raises USD49 Million in Series A Venture Financing 22
Unchained Labs Raises USD13 Million in Series C Financing 23
Tioma Therapeutics Raises USD86 Million in Series A Financing 24
Unchained Labs Raises USD25 Million in Series B Financing 25
Galera Therapeutics Raises Additional USD5 Million in Series B Financing 26
ObsEva Raises USD59 Million in Series B Financing Round 27
Galera Therapeutics Raises USD37 Million in Series B Financing 29
Corvus Pharma Raises USD75 Million in Series B Venture Financing 30
Ra Pharma Raises USD58.5 Million in Series B Financing 32
Unchained Labs Raises Additional USD6 Million in Series A Venture Financing 33
Kanyos Bio Raises USD16 Million in Venture Financing 34
Unchained Labs Raises USD25 Million in Series A Financing 35
CoLucid Pharma Raises USD37 Million in Series C Financing Round 36
Corvus Pharma Raises USD33.5 Million in Series A Venture Financing 38
Allakos Raises USD10 Million in Extended Series A Venture Financing 39
Anokion Raises US$37.5 Million In Series A Venture financing 40
Otonomy Raises US$49 Million In Series D Venture Financing 41
PanOptica Raises US$45 Million In Series B Financing 43
Alios BioPharma Raises US$41 Million In Series B Venture Financing 45
Thesan Pharma Raises US$49 Million In Series B Venture Financing 46
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 47
Delenex Therapeutics Raises US$8 Million In Series A3 Financing 48
Otonomy Raises US$46 Million In Series C Venture Financing 49
Flexion Therapeutics Raises US$20 Million In Series B Financing 51
Thesan Pharma Raises Additional US$12 Million In Series A Financing 52
Affimed Therapeutics Raises US$20.2 Million In Series D Financing 53
Epsilon Raises USD2 Million in Financing 55
Alder Biopharma Raises US$38 Million In Series D Financing 56
Elevation Pharma Secures US$30 Million In Series B Financing 57
Imagen Biotech Secures US$40 Million In Series A Venture Financing 59
Delenex Therapeutics Secures An Additional US$17.2 Million In Series A Financing Round 60
f-star Secures US$21.7 Million In Financing Round 62
Partnerships 64
Metacrine Enters into Agreement with Novo Nordisk 64
Novo Nordisk Enters into Research Agreement with University of Oxford 65
Novo Nordisk Enters into Research Agreement with UW Medicine 66
BioClinica Enters Into Agreement With NNIT For Clinical Trial Management System 67
Humana Enters Into Research Agreement With Novo Nordisk For Diabetes 68
Novo Nordisk Enters Into R&D Agreement With Juvenile Diabetes Research Foundation For Type 1 Diabetes 69
Novo Nordisk Enters Into Co-Development Agreement With Oxford University 70
Beijing Genomics Institute Enters Into Agreement With Novo Nordisk 71
Enlight Biosciences Enters Into Co-Development Agreement With AstraZeneca And Novo Nordisk 72
Adimab Enters Into Co-Development Agreement With Novo Nordisk 73
Licensing Agreements 74
Innate Pharma Enters into Licensing Agreement with Novo Nordisk 74
Novo Nordisk Enters into Licensing Agreement with Ablynx 75
Novo Nordisk Enters into Licensing Agreement with Emisphere 76
Novo Nordisk Enters into Licensing Agreement with Genmab 77
Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 78
Emisphere Technologies Amends Licensing Agreement With Novo Nordisk For GLP-1 Receptor 79
Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 80
Novo Nordisk Amends Licensing Agreement with Emisphere 81
Caisson Biotech Expands Licensing Agreement With Novo Nordisk For Heptune Drug Delivery Technology 82
Innate Pharma Enters Into Licensing Agreement With Novo Nordisk 83
Adimab Enters Into Licensing Agreement With Novo Nordisk 85
Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse 86
Pharmacyclics Enters Into Licensing Agreement With Novo Nordisk For PCI-27483 87
Novo Nordisk Announces Licensing Agreement With National Cheng Kung University For Anti-IL-20 88
Caisson Biotech Enters Into Licensing Agreement With Novo Nordisk For Heparosan-Based Drug Delivery Technology 89
Pacira Pharma Enters Into Licensing Agreement With Novo Nordisk 90
Equity Offering 91
Anokion to Raise USD16 Million in Private Placement of Shares 91
Tobira Therapeutics Raises USD27 Million in Private Placement of Shares 92
NNIT Prices IPO for USD191 Million 93
Asset Transactions 95
Novo Nordisk Plans to Sell Inflammation Business 95
Acquisition 96
Novo Nordisk May Acquire Global Blood Therapeutics 96
Novo Nordisk to Acquire Calibrium and MB2 97
Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To US$430 Million 98
Novo Nordisk AS – Key Competitors 100
Novo Nordisk AS – Key Employees 101
Novo Nordisk AS – Locations And Subsidiaries 102
Head Office 102
Other Locations & Subsidiaries 102
Recent Developments 107
Strategy And Business Planning 107
Sep 29, 2016: Novo Nordisk announces plans to reduce workforce by approximately 1,000 employees 107
Feb 10, 2016: Novo Nordisk highlights hemophilia, growth hormone medicine manufacturing with Danish and U.S. Ambassadors 108
Financial Announcements 109
Nov 01, 2017: Novo Nordisk increased reported operating profit by 5% in the first nine months of 2017 109
Aug 09, 2017: Novo Nordisk increased reported operating profit by 8% in the first six months of 2017 110
May 03, 2017: Novo Nordisk increased reported operating profit by 10% in the first three months of 2017 111
Feb 02, 2017: Novo Nordisk increased adjusted operating profit by 6% in local currencies in 2016 112
Oct 28, 2016: Novo Nordisk increased adjusted operating profit by 7% in local currencies in the first nine months of 2016 113
Aug 05, 2016: Novo Nordisk increased adjusted operating profit by 8% in local currencies in the first six months of 2016 114
Apr 29, 2016: Novo Nordisk increased adjusted operating profit by 10% in local currencies in the first quarter of 2016 115
Feb 03, 2016: Novo Nordisk increased operating profit by 43% in 2015 to DKK 49.4 billion 116
Corporate Communications 117
May 16, 2017: Change in composition of the Board of Directors of Novo Nordisk 117
May 16, 2017: Change in composition of the Board of Directors of Novo Nordisk 118
Sep 01, 2016: Lars Rebien Sorensen to retire as CEO of Novo Nordisk; Lars Fruergaard Jorgensen appointed as successor 119
Feb 12, 2016: Proposed changes in composition of the Board of Directors of Novo Nordisk 120
Legal and Regulatory 121
Jan 11, 2017: Bernstein Litowitz Berger & Grossmann LLP Announces Securities Class Action Suit Filed Against Novo Nordisk A/S and Certain of its Senior Executives 121
Government and Public Interest 122
Oct 31, 2017: New US study reveals key reasons why millions of people with obesity are not receiving adequate care 122
Jun 07, 2017: Lyfebulb and Novo Nordisk team up again to advance entrepreneur innovation in diabetes management 123
Apr 17, 2017: Novo Nordisk Foundation Grant 124
Nov 14, 2016: Novo Nordisk expands programme to reach 20,000 children with diabetes in developing countries 125
Nov 03, 2016: New study showed that only 55% of people with obesity have received a formal obesity diagnosis 126
Product News 127
11/30/2016: Ablynx Achieves First Milestone As Part Of Collaboration With Novo Nordisk 127
09/16/2016: Semaglutide reduced major cardiovascular events by 26% in adults with type 2 diabetes at high cardiovascular risk 128
09/15/2016: Victoza lowered the progression of kidney damage in adults with type 2 diabetes at high CV risk 129
09/13/2016: Semaglutide demonstrated superior HbA1c reduction vs placebo as add-on to basal insulin alone or with metformin in adults with type 2 diabetes 130
09/06/2017: Berg & Androphy: $46.5M Settlement in False Claims Act Case Over Alleged Illegal Marketing of Novo Nordisk Diabetes Drug Victoza 131
09/05/2017: Novo Nordisk announces conclusion of U.S. federal investigation of marketing practices 132
08/28/2017: Victoza reduces the risk of major cardiovascular events in people with type 2 diabetes with or without prior events 133
08/25/2017: Victoza approved in the US as the only type 2 diabetes treatment indicated to reduce the risk of major adverse cardiovascular events 134
07/27/2017: Victoza has been approved in the EU as the only GLP-1 with a label to include prevention of cardiovascular events 135
07/06/2016: Liraglutide reduces blood sugars in patients taking large amounts of insulin 136
06/23/2017: CHMP adopts positive opinion for EU label update of Victoza based on the LEADER trial 138
06/20/2017: Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes 139
06/13/2017: New LEADER analysis shows Victoza reduces cardiovascular risk in people with type 2 diabetes regardless of severe hypoglycaemia events 140
06/13/2016: GI Dynamics Announces Results of EndoBarrier Therapy Studies at Digestive Disease Week Meeting 141
06/13/2016: Victoza (liraglutide) significantly reduced the risk of major cardiovascular events and death in adults with type 2 diabetes in the LEADER trial 142
05/09/2016: GI Dynamics Releases Safety and Efficacy Data for EndoBarrier Therapy 143
05/03/2016: Saxenda demonstrated similar efficacy and safety profile across obesity severity stages 144
04/27/2017: Novo Nordisk Receives FDA Approval of Saxenda (liraglutide) injection 3 mg Label Update Including Long-Term Safety and Efficacy Data from 3-Year Trial 146
02/11/2016: Researchers urge further study on long-term safety of promising diabetes drug 147
Product Approvals 148
Jun 22, 2017: CHMP endorses EU label update of Saxenda based on the LEADER trial 148
Jun 16, 2017: FDA posts briefing materials prior to Advisory Committee meeting for Victoza label update 149
May 08, 2017: Novo Nordisk’s Saxenda Rejects For Use Within NHS Scotland 150
Feb 28, 2017: Novo Nordisk files for regulatory approval of once-weekly semaglutide for the treatment of type 2 diabetes in Japan 151
Dec 05, 2016: Novo Nordisk files for regulatory approval of once-weekly semaglutide in the US and EU for the treatment of type 2 diabetes 153
Oct 25, 2016: Novo Nordisk submits application to regulatory authorities to include LEADER data in Victoza label 155
Clinical Trials 156
May 17, 2017: Early response to Saxenda resulted in weight maintenance and additional weight loss over 56 weeks 156
Apr 03, 2017: Once-weekly semaglutide demonstrated consistent blood glucose reductions and weight loss regardless of background oral antidiabetic treatment 157
Sep 14, 2016: Saxenda Provides Consistent Weight Loss and Improvements in Blood Glucose Control Across BMI Categories After Three Years of Treatment 158
Sep 08, 2016: Diabetes drug focus of new clinical trial for Parkinson’s disease 159
Aug 02, 2016: FIGHT study proves type-2 diabetes therapy ineffective in the treatment of high-risk heart failure patients 160
Jun 12, 2016: Semaglutide demonstrated superior improvements in glycaemic control vs sitagliptin (SUSTAIN 2) and exenatide ER (SUSTAIN 3) in two clinical trials in adults with type 2 diabetes 161
Jun 02, 2016: Three-year Data Show Early Response to Saxenda Resulted in Improvements in Weight Loss and Cardiometabolic Risk Factors 163
May 27, 2016: Semaglutide Demonstrated Superior Glycaemic Control vs Insulin Glargine U100 in Adults with Type 2 Diabetes 164
Apr 28, 2016: Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial 165
Apr 04, 2016: Saxenda demonstrated significant improvements in cardiometabolic risk factors over three years compared with placebo 166
Apr 02, 2016: Semaglutide demonstrated superior improvements in glycaemic control vs placebo in adults with type 2 diabetes 167
Mar 04, 2016: Victoza significantly reduces the risk of major adverse cardiovascular events in the LEADER trial 168
Feb 23, 2016: Novo Nordisk successfully completes fifth phase 3a trial with semaglutide in people with type 2 diabetes 169
Other Significant Developments 171
Mar 16, 2017: CVS Health Launches Reduced Rx Savings Program to Give Patients Access to More Affordable Medications 171
Jul 04, 2016: Novo Nordisk invests DKK 400 million in an expanded production plant in Kalundborg 172
Apr 21, 2016: Novo Nordisk plans to invest more than 100 million euros in production plants in Chartres, France 173
Appendix 174
Methodology 174
About GlobalData 174
Contact Us 174
Disclaimer 174

List of Tables
Novo Nordisk AS, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 9
Novo Nordisk AS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 10
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 11
Novo Nordisk AS, Deals By Therapy Area, 2011 to YTD 2017 12
Novo Nordisk AS, Medical Devices Deals, 2011 to YTD 2017 14
Novo Nordisk AS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 15
Inozyme Pharma Raises USD49 Million in Series A Venture Financing 22
Unchained Labs Raises USD13 Million in Series C Financing 23
Tioma Therapeutics Raises USD86 Million in Series A Financing 24
Unchained Labs Raises USD25 Million in Series B Financing 25
Galera Therapeutics Raises Additional USD5 Million in Series B Financing 26
ObsEva Raises USD59 Million in Series B Financing Round 27
Galera Therapeutics Raises USD37 Million in Series B Financing 29
Corvus Pharma Raises USD75 Million in Series B Venture Financing 30
Ra Pharma Raises USD58.5 Million in Series B Financing 32
Unchained Labs Raises Additional USD6 Million in Series A Venture Financing 33
Kanyos Bio Raises USD16 Million in Venture Financing 34
Unchained Labs Raises USD25 Million in Series A Financing 35
CoLucid Pharma Raises USD37 Million in Series C Financing Round 36
Corvus Pharma Raises USD33.5 Million in Series A Venture Financing 38
Allakos Raises USD10 Million in Extended Series A Venture Financing 39
Anokion Raises US$37.5 Million In Series A Venture financing 40
Otonomy Raises US$49 Million In Series D Venture Financing 41
PanOptica Raises US$45 Million In Series B Financing 43
Alios BioPharma Raises US$41 Million In Series B Venture Financing 45
Thesan Pharma Raises US$49 Million In Series B Venture Financing 46
HTG Molecular Diagnostics Raises Funds Through Extended Series E Financing 47
Delenex Therapeutics Raises US$8 Million In Series A3 Financing 48
Otonomy Raises US$46 Million In Series C Venture Financing 49
Flexion Therapeutics Raises US$20 Million In Series B Financing 51
Thesan Pharma Raises Additional US$12 Million In Series A Financing 52
Affimed Therapeutics Raises US$20.2 Million In Series D Financing 53
Epsilon Raises USD2 Million in Financing 55
Alder Biopharma Raises US$38 Million In Series D Financing 56
Elevation Pharma Secures US$30 Million In Series B Financing 57
Imagen Biotech Secures US$40 Million In Series A Venture Financing 59
Delenex Therapeutics Secures An Additional US$17.2 Million In Series A Financing Round 60
f-star Secures US$21.7 Million In Financing Round 62
Metacrine Enters into Agreement with Novo Nordisk 64
Novo Nordisk Enters into Research Agreement with University of Oxford 65
Novo Nordisk Enters into Research Agreement with UW Medicine 66
BioClinica Enters Into Agreement With NNIT For Clinical Trial Management System 67
Humana Enters Into Research Agreement With Novo Nordisk For Diabetes 68
Novo Nordisk Enters Into R&D Agreement With Juvenile Diabetes Research Foundation For Type 1 Diabetes 69
Novo Nordisk Enters Into Co-Development Agreement With Oxford University 70
Beijing Genomics Institute Enters Into Agreement With Novo Nordisk 71
Enlight Biosciences Enters Into Co-Development Agreement With AstraZeneca And Novo Nordisk 72
Adimab Enters Into Co-Development Agreement With Novo Nordisk 73
Innate Pharma Enters into Licensing Agreement with Novo Nordisk 74
Novo Nordisk Enters into Licensing Agreement with Ablynx 75
Novo Nordisk Enters into Licensing Agreement with Emisphere 76
Novo Nordisk Enters into Licensing Agreement with Genmab 77
Novo Nordisk Enters into Licensing Agreement with Janssen Biotech 78
Emisphere Technologies Amends Licensing Agreement With Novo Nordisk For GLP-1 Receptor 79
Bristol-Myers Squibb Enters into Licensing Agreement with Novo Nordisk 80
Novo Nordisk Amends Licensing Agreement with Emisphere 81
Caisson Biotech Expands Licensing Agreement With Novo Nordisk For Heptune Drug Delivery Technology 82
Innate Pharma Enters Into Licensing Agreement With Novo Nordisk 83
Adimab Enters Into Licensing Agreement With Novo Nordisk 85
Novo Nordisk Enters Into Licensing Agreement With Kymab For Kymouse 86
Pharmacyclics Enters Into Licensing Agreement With Novo Nordisk For PCI-27483 87
Novo Nordisk Announces Licensing Agreement With National Cheng Kung University For Anti-IL-20 88
Caisson Biotech Enters Into Licensing Agreement With Novo Nordisk For Heparosan-Based Drug Delivery Technology 89
Pacira Pharma Enters Into Licensing Agreement With Novo Nordisk 90
Anokion to Raise USD16 Million in Private Placement of Shares 91
Tobira Therapeutics Raises USD27 Million in Private Placement of Shares 92
NNIT Prices IPO for USD191 Million 93
Novo Nordisk Plans to Sell Inflammation Business 95
Novo Nordisk May Acquire Global Blood Therapeutics 96
Novo Nordisk to Acquire Calibrium and MB2 97
Sunovion Pharma Completes Acquisition Of Elevation Pharma For Up To US$430 Million 98
Novo Nordisk AS, Key Competitors 100
Novo Nordisk AS, Key Employees 101
Novo Nordisk AS, Subsidiaries 102

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Novo Nordisk AS (NOVO B)-製薬・医療分野:企業M&A・提携分析(Novo Nordisk AS (NOVO B) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆